MRNA vs. DNA

Last updated Apr 2, 2026

Compare and contrast key facts about Moderna, Inc. (MRNA) and Ginkgo Bioworks Holdings, Inc. (DNA).

Performance

MRNA vs. DNA - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Moderna, Inc. (MRNA) and Ginkgo Bioworks Holdings, Inc. (DNA). The values are adjusted to include any dividend payments, if applicable.

MRNA vs. DNA - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
MRNA Moderna, Inc.	69.65%	-29.08%	-58.19%	-44.63%	-29.28%	56.86%
DNA Ginkgo Bioworks Holdings, Inc.	-26.23%	-15.38%	-85.47%	0.00%	-79.66%	-17.89%

Fundamentals

Market Cap MRNA : $19.61B DNA : $339.96M
EPS MRNA : -$7.24 DNA : -$5.65
PS Ratio MRNA : 10.04 DNA : 1.99
PB Ratio MRNA : 2.27 DNA : 0.67
Total Revenue (TTM) MRNA : $1.94B DNA : $170.16M
Gross Profit (TTM) MRNA : $274.00M DNA : $138.63M
EBITDA (TTM) MRNA : -$2.61B DNA : -$215.86M

Returns By Period

In the year-to-date period, MRNA achieves a 69.65% return, which is significantly higher than DNA's -26.23% return.

MRNA

• 1D: -1.52%
• 1M: -5.33%
• YTD: 69.65%
• 6M: 81.27%
• 1Y: 84.20%
• 3Y*: -31.19%
• 5Y*: -17.71%
• 10Y*: —

DNA

• 1D: 11.86%
• 1M: -9.19%
• YTD: -26.23%
• 6M: -57.96%
• 1Y: 7.54%
• 3Y*: -51.34%
• 5Y*: —
• 10Y*: —

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

MRNA vs. DNA — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

MRNA

MRNA Risk / Return Rank: 77
MRNA Sharpe Ratio Rank: 80
MRNA Sortino Ratio Rank: 78
MRNA Omega Ratio Rank: 73
MRNA Calmar Ratio Rank: 78
MRNA Martin Ratio Rank: 74

DNA

DNA Risk / Return Rank: 46
DNA Sharpe Ratio Rank: 45
DNA Sortino Ratio Rank: 53
DNA Omega Ratio Rank: 51
DNA Calmar Ratio Rank: 42
DNA Martin Ratio Rank: 42

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

MRNA vs. DNA - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Moderna, Inc. (MRNA) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	MRNA	DNA	Difference
Sharpe ratio Return per unit of total volatility	1.28	0.08	+1.20
Sortino ratio Return per unit of downside risk	2.02	0.86	+1.16
Omega ratio Gain probability vs. loss probability	1.24	1.10	+0.13
Calmar ratio Return relative to maximum drawdown	2.15	0.00	+2.15
Martin ratio Return relative to average drawdown	4.44	0.01	+4.44
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

MRNA vs. DNA - Sharpe Ratio Comparison

The current MRNA Sharpe Ratio is 1.28, which is higher than the DNA Sharpe Ratio of 0.08. The chart below compares the historical Sharpe Ratios of MRNA and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	MRNA	DNA	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.28	0.08	+1.20
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	-0.27	—	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.20	-0.59	+0.79

Correlation

The correlation between MRNA and DNA is 0.36, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

MRNA vs. DNA - Dividend Comparison

Neither MRNA nor DNA has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

MRNA vs. DNA - Drawdown Comparison

The maximum MRNA drawdown since its inception was -95.38%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for MRNA and DNA.

Drawdown Indicators

	MRNA	DNA	Difference
Max Drawdown Largest peak-to-trough decline	-95.38%	-99.10%	+3.72%
Max Drawdown (1Y) Largest decline over 1 year	-35.51%	-66.05%	+30.54%
Max Drawdown (5Y) Largest decline over 5 years	-95.38%	—	—
Current Drawdown Current decline from peak	-89.67%	-98.97%	+9.30%
Average Drawdown Average peak-to-trough decline	-55.87%	-78.98%	+23.11%
Ulcer Index Depth and duration of drawdowns from previous peaks	17.21%	32.41%	-15.20%

Volatility

MRNA vs. DNA - Volatility Comparison

The current volatility for Moderna, Inc. (MRNA) is 22.27%, while Ginkgo Bioworks Holdings, Inc. (DNA) has a volatility of 28.02%. This indicates that MRNA experiences smaller price fluctuations and is considered to be less risky than DNA based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	MRNA	DNA	Difference
Volatility (1M) Calculated over the trailing 1-month period	22.27%	28.02%	-5.75%
Volatility (6M) Calculated over the trailing 6-month period	50.95%	73.00%	-22.05%
Volatility (1Y) Calculated over the trailing 1-year period	66.40%	100.38%	-33.98%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	66.59%	96.65%	-30.06%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	72.29%	96.65%	-24.36%

Financials